ArticleBlood2013
Why is it so difficult to use gemtuzumab ozogamicin?
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trial watch: antibody-drug conjugates in cancer therapy.Oncoimmunology · 2026Review
- Strategies and challenges for the next generation of antibody-drug conjugates.Nature reviews. Drug discovery · 2017Review
- Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia.Stem cells international · 2016Review
- Conjugates of Small Molecule Drugs with Antibodies and Other Proteins.Biomedicines · 2014Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of Blood, Petersdorf et al report negative results of the phase 3 study designed by the Southwest Oncology Group (SWOG), which tested the addition of gemtuzumab ozogamicin (GO) to a 317 regimen in a randomized fashion in adult patients newly diagnosed with acute myeloid leukemia (AML) who are younger than 60 years. Also in this issue of Blood, Rowe and Löwenberg discuss results of this study in the context of 4 other controlled studies (1 negative and 1 positive in a predefined subset of patients, and 2 positive) performed during the same period in Europe.
Indexed as
Identifiers
23766456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.